BENZOYL PEROXIDE- benzoyl peroxide solution 
Glenmark Generics Inc., USA

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Benzoyl Peroxide Creamy Wash 4% and 8%

ACNE WASH FOR TOPICAL USE

ACNE WASH KIT FOR TOPICAL USE

Rx only

DESCRIPTION

Benzoyl peroxide creamy wash 4% and 8% are topical preparations containing benzoyl peroxide as the active ingredient. Benzoyl peroxide creamy wash 4% and 8% contain 4% and 8% benzoyl peroxide, respectively, in a lathering cream vehicle containing alpha olefin sulfonate, cetostearyl alcohol, glycerin, glyceryl monostearate SE, methylparaben, phosphoric acid, propylene glycol, sodium PCA, white petrolatum and purified water.

The structural formula of benzoyl peroxide is:

Structural Formula of Benzoyl Peroxide

CLINICAL PHARMACOLOGY

The exact method of action of benzoyl peroxide in acne vulgaris is not known. Benzoyl peroxide is an antibacterial agent with demonstrated activity against Propionibacterium acnes. This action, combined with the mild keratolytic effect of benzoyl peroxide is believed to be responsible for its usefulness in acne.

Benzoyl peroxide is absorbed by the skin where it is metabolized to benzoic acid and excreted as benzoate in the urine.

INDICATIONS AND USAGE

Benzoyl peroxide creamy wash 4% and 8% are indicated for use in the topical treatment of mild to moderate acne vulgaris. Benzoyl peroxide creamy wash 4% and 8% may be used as an adjunct in acne treatment regimens including antibiotics, retinoic acid products, and sulfur/ salicylic acid containing preparations.

CONTRAINDICATIONS

Benzoyl peroxide creamy wash 4% and 8% should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients in the product.

PRECAUTIONS

General

For external use only. Avoid contact with eyes and mucous membranes. AVOID CONTACT WITH HAIR, FABRICS OR CARPETING ASBENZOYL PEROXIDE WILL CAUSE BLEACHING.

Carcinogenesis, mutagenesis, impairment of fertility

Based upon all available evidence, benzoyl peroxide is not considered to be a carcinogen. However, data from a study using mice known to be highly susceptible to cancer suggest that benzoyl peroxide acts as a tumor promoter. The clinical significance of the findings is not known.

Pregnancy

Pregnancy Category C – Animal reproduction studies have not been conducted with benzoyl peroxide. It is not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzoyl peroxide should be used by a pregnant woman only if clearly needed.

Nursing mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when benzoyl peroxide is administered to a nursing woman.

Pediatric use

Safety and effectiveness in children below the age of 12 have not been established.

ADVERSE REACTIONS

Contact sensitization reactions are associated with the use of topical benzoyl peroxide products and may be expected to occur in 10 to 25 of 1000 patients. The most frequent adverse reactions associated with benzoyl peroxide use are excessive erythema and peeling which may be expected to occur in 5 of 100 patients. Excessive erythema and peeling most frequently appear during the initial phase of drug use and may normally be controlled by reducing frequency of use.

DOSAGE AND ADMINISTRATION

Shake well before using. Wash the affected areas once a day during the first week, and twice a day thereafter as tolerated. Wet skin areas to be treated; apply benzoyl peroxide creamy wash 4% or 8%, work to a full lather, rinse thoroughly and pat dry. Frequency of use should be adjusted to obtain the desired clinical response. Clinically visible improvement will normally occur by the third week of therapy. Maximum lesion reduction may be expected after approximately eight to twelve weeks of drug use. Continuing use of the drug is normally required to maintain a satisfactory clinical response.

HOW SUPPLIED

Benzoyl peroxide creamy wash 4% is supplied in 170 gm (6 oz) tubes:
NDC 68462-414-38

Acne wash kit includes Benzoyl peroxide creamy wash 4% 170 gm (6 oz) and Soap-free cleanser lotion 106 ml (3.6 fl oz):
NDC 68462-548-38

Benzoyl peroxide creamy wash 8% is supplied in 170 gm (6 oz) tubes:
NDC 68462-415-38

Acne wash kit includes Benzoyl peroxide creamy wash 8% 170 gm (6 oz) and Soap-free cleanser lotion 106 ml (3.6 fl oz):
NDC 68462-549-38

Store at 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Manufactured by:

Glenmark Generics Ltd.
Colvale-Bardez, Goa 403 513, India

Manufactured for:

Glenmark Logo

Glenmark Generics Inc., USA
Mahwah, NJ 07430

Questions? 1 (888)721-7115
www.glenmarkgenerics.com

January 2010

4% Principal Display Panel

4% Tube Label

4% Kit Principal Display Panel

4% Acne Wash Kit Label

8% Principal Display Panel

8% Tube Label

8% Kit Principal Display Panel

8% Acne Wash Kit Label
BENZOYL PEROXIDE 
benzoyl peroxide solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:68462-414
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BENZOYL PEROXIDE (BENZOYL PEROXIDE) BENZOYL PEROXIDE4 g  in 100 g
Inactive Ingredients
Ingredient NameStrength
CETOSTEARYL ALCOHOL 
GLYCERIN 
GLYCERYL MONOSTEARATE 
METHYLPARABEN 
PHOSPHORIC ACID 
PROPYLENE GLYCOL 
SODIUM PYRROLIDONE CARBOXYLATE 
PETROLATUM 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:68462-414-38170 g in 1 TUBE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/30/200903/01/2011
BENZOYL PEROXIDE 
benzoyl peroxide solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:68462-548
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BENZOYL PEROXIDE (BENZOYL PEROXIDE) BENZOYL PEROXIDE4 g  in 100 g
Inactive Ingredients
Ingredient NameStrength
CETOSTEARYL ALCOHOL 
GLYCERIN 
GLYCERYL MONOSTEARATE 
METHYLPARABEN 
PHOSPHORIC ACID 
PROPYLENE GLYCOL 
SODIUM PYRROLIDONE CARBOXYLATE 
PETROLATUM 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:68462-548-38170 g in 1 CARTON
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/30/200903/01/2011
BENZOYL PEROXIDE 
benzoyl peroxide solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:68462-415
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BENZOYL PEROXIDE (BENZOYL PEROXIDE) BENZOYL PEROXIDE8 g  in 100 g
Inactive Ingredients
Ingredient NameStrength
CETOSTEARYL ALCOHOL 
GLYCERIN 
GLYCERYL MONOSTEARATE 
METHYLPARABEN 
PHOSPHORIC ACID 
PROPYLENE GLYCOL 
SODIUM PYRROLIDONE CARBOXYLATE 
PETROLATUM 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:68462-415-38170 g in 1 CARTON
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/30/200903/01/2011
BENZOYL PEROXIDE 
benzoyl peroxide solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:68462-549
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BENZOYL PEROXIDE (BENZOYL PEROXIDE) BENZOYL PEROXIDE8 g  in 100 g
Inactive Ingredients
Ingredient NameStrength
CETOSTEARYL ALCOHOL 
GLYCERIN 
GLYCERYL MONOSTEARATE 
METHYLPARABEN 
PHOSPHORIC ACID 
PROPYLENE GLYCOL 
SODIUM PYRROLIDONE CARBOXYLATE 
PETROLATUM 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:68462-549-38170 g in 1 CARTON
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other01/30/200903/01/2011
Labeler - Glenmark Generics Inc., USA (130597813)
Establishment
NameAddressID/FEIBusiness Operations
Glenmark Generics Limited677318665ANALYSIS(68462-414, 68462-548, 68462-415, 68462-549), MANUFACTURE(68462-414, 68462-548, 68462-415, 68462-549)

Revised: 6/2014
 
Glenmark Generics Inc., USA